The Thai Phase III Trial (RV144) Vaccine Regimen Induces T Cell Responses That Preferentially Target Epitopes within the V2 Region of HIV-1 EnvelopeMark de Souza, Silvia Ratto‐Kim, Weerawan Chuenarom et al.|The Journal of Immunology|2012Cited by 140
Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn InfantsColeen K. Cunningham, Karin Nielsen‐Saines, Lynne Mofenson et al.|The Journal of Infectious Diseases|2019Cited by 62